Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

61. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe

Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe Perkerson K A, Gillespie E L, Coleman C I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several statin monotherapies and combination therapies of statin with ezetimibe (E) were examined. The statins evaluated were: atorvastatin (A) at doses of 10, 20, 40 and 80 mg; fluvastatin (F) at doses of 20, 40 and 80 mg; lovastatin (L) at doses of 10, 20 and 40 mg; pravastatin (P) at doses of 10, 20, 40 and 80 mg; rosuvastatin (R) at doses of 5, 10, 20 and 40 mg; and simvastatin (S) at doses

NHS Economic Evaluation Database.2005

62. Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol

Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol Gryskiewicz K A, Coleman C I, Gillespie E L, White C M Record Status This is a critical abstract (...) assessed were lovastatin, pravastatin, simvastatin and atorvastatin, each in combination with ezetimibe. Dosages from 5 to 80 mg were used. Further details of the technologies were not reported. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The details of the study population were not explicitly reported, although the authors stated that they searched for "clinical trials with similar sample size and study methodology". No further details were

NHS Economic Evaluation Database.2005

64. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway

Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway Cook J R, Yin D, Alemao E, Davies G, Krobot K J, Veltri E, Lipka L, Badia (...) X Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ezetimibe co-administration in statin-treated patients who have failed to reach their lipid goal, for the primary and secondary prevention of coronary

NHS Economic Evaluation Database.2004

65. New Drugs VIII ? Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®)

New Drugs VIII ? Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®) [51] New Drugs VIII – Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®) | Therapeutics Initiative Independent Healthcare Evidence > > [51] New Drugs VIII – Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®) and Tacrolimus (Protopic ® ) Telithromycin (Ketek (...) of therapy for CAP: erythromycin $5, azithromycin $32, clarithromycin $32-64. CONCLUSION : Telithromycin is of similar efficacy to but has more adverse effects than clarithromycin, the one macrolide to which it has been compared. Ezetimibe (Ezetrol ® ) Approved indication: Hypercholesterolemia administered alone or with a statin. Mechanism of action: Ezetimibe is the first lipid lowering compound that selectively inhibits the intestinal absorption of cholesterol. Pharmacokinetics: Ezetimibe is rapidly

Therapeutics Letter2004

66. Ezetimibe for lowering blood cholesterol

Ezetimibe for lowering blood cholesterol Ezetimibe for lowering blood cholesterol Ezetimibe for lowering blood cholesterol Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Ezetimibe for lowering blood cholesterol (...) . Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003 Authors' objectives To summarize the available information on the use of ezetimibe (Ezetrol(TM) in Canada, Zetia(TM) in the United States, manufactured by Merck Frosst-Schering) to reduce the rate of cholesterol absorption by the human small intestine. Authors' conclusions Trials to assess safety and tolerability beyond 12 weeks are ongoing. Cost-effectiveness analyses speculating on reductions in death and morbidity

Health Technology Assessment (HTA) Database.2003

67. Ezetimibe (Ezetrol) - Primary hypercholesterolaemia

Ezetimibe (Ezetrol) - Primary hypercholesterolaemia Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Ezetimibe (Ezetrol Ò ) No. 61/03 Merck Sharpe & Dohme / Schering-Plough Ltd (UK) Summary of Recommendation 8 September 2003 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its (...) use in NHS Scotland. The recommendation is summarised as follows: ADVICE Recommended for restricted use within NHS Scotland RECOMMENDATION Ezetimibe may be considered in combination with a statin for patients who have failed to reach target cholesterol levels despite treatment with titrated/optimised statins alone. It may also be considered as monotherapy where statins are inappropriate or poorly tolerated. Professor David H Lawson Chairman

Scottish Medicines Consortium2003

68. Ezetimibe - horizon scanning review

Ezetimibe - horizon scanning review Ezetimibe - horizon scanning review Ezetimibe - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Ezetimibe - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise (...) the current research evidence on ezetimibe for hyperlipidaemia. Authors' conclusions - Clinical impact: The long-term gains of a reduction in the risk of future CV events following any reduction in individual and population cardiac risk factors including lipid profiles, is potentially highly significant. - Service impact: There will be no additional impact (over and above the impact of the CHD NSF) on health services with the introduction of ezetimibe. - Patient issues: Ezetimibe will represent another

Health Technology Assessment (HTA) Database.2001